header logo image


Page 671«..1020..670671672673..680690..»

Global Molecular Microbiology Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2025 – News Times

February 22nd, 2020 4:44 pm

The report titled Global Molecular Microbiology Market is one of the most comprehensive and important additions to Reportspedia archive of market research diaries. It offers thorough research and analysis of major aspects including market size, market growth rate, market profitability, industry cost structure, distribution channel, market trends, and key success factors of the market.

The report includes SWOT and PESTLE analyses to provide a deeper understanding of the industry. All of the foremost companies included in the report are profiled based on gross margin, market share, forthcoming strategies, recent expansions, target customer demographics, products and applications, and other critical factors. The report also offers regional analysis of the Molecular Microbiology market with high focus on market growth, growth rate, and growth potential.

Global Molecular Microbiology Market is valued at USD XX million in 2019 and is projected to reach US$ XX million till 2025, rising at a CAGR of 7.8% during the period 2019 to 2025.

Major Players involved in the Global Molecular Microbiology Market:

Roche, Myriad Genetics, Abbott, Qiagen, Danaher (Cepheid), Illumina, Agilent, BioMerieux, Hologic, DAAN Gene, Genomic Health, BD, Foundation Medicine,

Get Free PDF Sample Report(Including Full TOC, List of Tables & Figures, Chart):https://www.reportspedia.com/report/life-sciences/global-molecular-microbiology-market-2020-by-company,-regions,-type-and-application,-forecast-to-2025/50888#request_sample

Market Competition

The vendor landscape and competitive scenarios of the global Molecular Microbiology industry are broadly analyzed to help market players gain competitive advantage over their competitors. Market players can use the analysis to prepare themselves for any future challenges well in advance. They will also be able to identify opportunities to attain a position of strength in the global Molecular Microbiology industry. Furthermore, the examination will help them to successfully channelize their strategies, strengths, and resources to gain maximum advantage.

The Essential Content Covered in the Global Molecular Microbiology Industry Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

The Molecular Microbiology Industry segment by regions includes:

Americas (United States, Canada, Mexico, and Brazil), APAC (China, Japan, Korea, Southeast Asia, India, and Australia), Europe (Germany, France, UK, Italy, Russia, and Spain), and Middle East & Africa (Egypt, South Africa, Israel, Turkey, and GCC Countries).

Global Molecular Microbiology Market Segmentation by Product:

By Type Molecular Microbiology market has been segmented into Quantitative PCR Detection Diagnostic Kits, Pathogenic Microorganisms Diagnostic Kits, etc.

Global Molecular Microbiology Market Segmentation by Application:

By Application Molecular Microbiology has been segmented into Human, Veterinary, etc.

Inquire Here For Queries Or Report Customization: : https://www.reportspedia.com/report/life-sciences/global-molecular-microbiology-market-2020-by-company,-regions,-type-and-application,-forecast-to-2025/50888#inquiry-before-buying

Key Questions Answered

1) What will be the size and CAGR of the global Molecular Microbiology market in 2025?

2) Which product will gain the highest request?

3) Which application could show the best development/growth?

4) What will be the competitive landscape in future?

5) Which players will lead the global Molecular Microbiology market in the coming years?

6) Which region will gain the largest share of the industry?

The report offers comprehensive analysis of the value chain, production, consumption, sales, and opportunities in the global Molecular Microbiology market. Market players can also use it to get useful endorsements and suggestions from market experts and knowledgeable industry analysts.

Table of Contents

Executive Summary

1 Industry Overview

2 Industry Chain Analysis

3 Manufacturing Technology of Molecular Microbiology market

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Molecular Microbiology market by Regions, Creators, Types and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Molecular Microbiology industry 2015-2019

7 Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Molecular Microbiology market by Regions

8 Gross and Gross Margin Examination

9 Marketing Traders or Distributor Examination

10 Worldwide Impacts on Molecular Microbiology Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Molecular Microbiology Industry 2019 Market Research Report

Continued

Click here to view the full report:https://www.reportspedia.com/report/life-sciences/global-molecular-microbiology-market-2020-by-company,-regions,-type-and-application,-forecast-to-2025/50888#table_of_contents

Link:
Global Molecular Microbiology Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2025 - News Times

Read More...

Protein Prevents Neuropathy From Chemotherapy – Technology Networks

February 22nd, 2020 4:43 pm

A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy in cancer patients who receive chemotherapy.

Chemotherapy is one of the most commonly recommended treatments for many forms of cancer. One major side effect, however, is peripheral neuropathy, or the damage or dysfunction of one or more nerves that typically results in numbness, tingling, muscle weakness and pain in the affected area. It frequently starts in a patient's hands and feet, though other regions and parts of the body can also be affected.

At the moment, there is no way to prevent or treat neuropathy caused by chemotherapy drugs. The only option is to limit or discontinue the chemotherapy treatment. As a result, many patients are not able to tolerate chemotherapy well.

In a recent study published by theJournal of Biological Chemistry, a team of researchers jointly led by Assistant Professor Raymond Deron Herr and Assistant Professor Raghav Sundar from the NUS Yong Loo Lin School of Medicine set out to examine whether S1P2, a receptor protein that resides on the surface of cells in the nervous system, is a potential target in the treatment of chemotherapy-induced neuropathy. The team first looked at the effects of platinum-based chemotherapy drugs, such as cisplatin, on the regulation of S1P2 and found that chemotherapy alters S1P2 activity. The team further demonstrated that the activation of S1P2 with a drug-like compound, can protect the nerve cells from damage and pain. This is in contrast to the accumulation of free radicals in nerves, leading to nerve degeneration when the receptor is removed. The team concluded that it is possible to block both the nerve injury and the pain when S1P2 is activated with a drug while administering cisplatin.

There are three major classes of drugs that cause neuropathy: platinum compounds (cisplatin and oxaliplatin), taxanes (paclitaxel), and a targeted medication known as bortezomib.

"While the study focused on the effects of cisplatin, based on what we know about the molecular processes, it is likely that an S1P2 drug will work in all cases of chemotherapy-induced neuropathy. Furthermore, it is possible that such a drug could treat many other forms of neuropathy, such as those caused by nerve injury, autoimmune disease, or diabetes," said Dr Herr.

"Neuropathy or numbness from chemotherapy is a common and debilitating side-effect faced by patients, with few proven treatments. Our study provides a deeper understanding of the biology of this condition, allowing potential treatments to reduce chemotherapy-induced neuropathy to be developed. We are currently exploring new drug molecules that would allow the activation of S1P2 in a more effective and stable manner," added Dr Sundar, who is also a Consultant with the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS) and the National University Hospital.

Reference: Wang, et al. (2020) Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal of Biological Chemistry DOI:10.1074/jbc.RA119.011699

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
Protein Prevents Neuropathy From Chemotherapy - Technology Networks

Read More...

Yoga to acupuncture: Alternative therapies to prevent diabetic neuropathy – Business Standard

February 22nd, 2020 4:43 pm

High levels of glucose in the blood can damage the peripheral nerves in your body, causing decreased sensation in the feet and hands as well as problems to the urinary tract, digestive system, and heart. With over 60 per cent of diabetics eventually developing peripheral neuropathy, it is one of the main secondary complications they face. Mild to moderate symptoms include pain, numbness and tingling sensation in the feet and legs. Fortunately, diabetic neuropathy can be prevented if strict control is maintained on blood sugar levels on a daily basis. Lifestyle changes and complementary therapies can help achieve this effectively. Three of the most commonly practiced alternative therapies to help prevent diabetic neuropathy are naturopathy, yoga and acupuncture.

Acupuncture

Acupuncture uses the science of inserting long, fine needles at various points in the body to stimulate the sensory receptors and stimulate them. A study published in the Journal of Thai Traditional and Alternative Medicine found that acupuncture drastically improves the positive effects of diabetes medication and alleviates the symptoms of diabetic neuropathy. Once they started the acupuncture regimen, the success rate of the symptom score went up from 8 percent to 90 per cent. The neuropathic disability score also went up from 37.45 to 90 once acupuncture was introduced into the treatment regimen.

Naturopathic and yogic interventions to improve diabetic neuropathy

Diet and exercise: The best defense against progressive damage from diabetic neuropathy is to manage the disease itself. Keep your blood sugar levels in check by eating healthy. Ensure that your diet includes a lot of fiber rich foods and whole grains, and very little saturated and trans fats. Structured physical interventions also play an important role in keeping blood sugar levels in check. Make sure you get at least 30 minutes of aerobic exercise every day. Meditation and deep breathing can help you manage chronic stress.

Supplements: Winter ginseng is very effective at keeping the blood sugar in control and managing the symptoms of peripheral neuropathy. Not only does it help increase the level of serum insulin, it also improves the insulin sensitivity of muscle cells as well as the bodys glucose tolerance, thereby easing the severity of diabetic neuropathy.

Yoga poses for the management of neuropathy

Yoga helps improve blood flow to the extremities, improves the bodys glucose tolerance and insulin sensitivity.

Exercise for feet and hands: Sit down in padmasana and extend your arms fully in front of your chest. This pose will help stretch both fingers and toes. It will help improve blood flow to the periphery and strengthen your nerves. If you can do it for a few minutes every day, you will start to experience relief.

Poses for diabetic neuropathy: If the condition is not severe, then traditional hatha yoga poses like trikonasana, ustrasana and dhanurasana will do. If the neuropathy is more advanced, it needs gentler practice under the guidance of a trained instructor. However, you can still benefit from gentle twist exercises, meditation and closely supervised backbends.

More:
Yoga to acupuncture: Alternative therapies to prevent diabetic neuropathy - Business Standard

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Research Report by Manufactures, Types, Applications and Forecast to 2025 …

February 22nd, 2020 4:43 pm

The report titled Global Chemotherapy Induced Peripheral Neuropathy Treatment Market is one of the most comprehensive and important additions to Reportspedia archive of market research diaries. It offers thorough research and analysis of major aspects including market size, market growth rate, market profitability, industry cost structure, distribution channel, market trends, and key success factors of the market.

The report includes SWOT and PESTLE analyses to provide a deeper understanding of the industry. All of the foremost companies included in the report are profiled based on gross margin, market share, forthcoming strategies, recent expansions, target customer demographics, products and applications, and other critical factors. The report also offers regional analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment market with high focus on market growth, growth rate, and growth potential.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market is valued at USD XX million in 2019 and is projected to reach US$ XX million till 2025, rising at a CAGR of 6.2% during the period 2019 to 2025.

Major Players involved in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market:

Aptinyx Inc, Sova Pharmaceuticals Inc, MAKScientific LLC, Asahi Kasei Pharma Corp, PledPharma, Regenacy Pharmaceuticals, Immune Pharmaceuticals Inc, Nemus Bioscience Inc, Metys Pharmaceuticals AG, DermaXon LLC, WinSanTor, Kineta Inc, Solasia Pharma K.K., Apexian Pharma, Krenitsky Pharmaceuticals Inc, PeriphaGen,

Get Free PDF Sample Report(Including Full TOC, List of Tables & Figures, Chart):https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#request_sample

Market Competition

The vendor landscape and competitive scenarios of the global Chemotherapy Induced Peripheral Neuropathy Treatment industry are broadly analyzed to help market players gain competitive advantage over their competitors. Market players can use the analysis to prepare themselves for any future challenges well in advance. They will also be able to identify opportunities to attain a position of strength in the global Chemotherapy Induced Peripheral Neuropathy Treatment industry. Furthermore, the examination will help them to successfully channelize their strategies, strengths, and resources to gain maximum advantage.

The Essential Content Covered in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

The Chemotherapy Induced Peripheral Neuropathy Treatment Industry segment by regions includes:

Americas (United States, Canada, Mexico, and Brazil), APAC (China, Japan, Korea, Southeast Asia, India, and Australia), Europe (Germany, France, UK, Italy, Russia, and Spain), and Middle East & Africa (Egypt, South Africa, Israel, Turkey, and GCC Countries).

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Product:

By Type Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others, etc.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Application:

By Application Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into Platinum Agents, Taxanes, Vinca Alkaloids, Others, etc.

Inquire Here For Queries Or Report Customization: : https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#inquiry-before-buying

Key Questions Answered

1) What will be the size and CAGR of the global Chemotherapy Induced Peripheral Neuropathy Treatment market in 2025?

2) Which product will gain the highest request?

3) Which application could show the best development/growth?

4) What will be the competitive landscape in future?

5) Which players will lead the global Chemotherapy Induced Peripheral Neuropathy Treatment market in the coming years?

6) Which region will gain the largest share of the industry?

The report offers comprehensive analysis of the value chain, production, consumption, sales, and opportunities in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. Market players can also use it to get useful endorsements and suggestions from market experts and knowledgeable industry analysts.

Table of Contents

Executive Summary

1 Industry Overview

2 Industry Chain Analysis

3 Manufacturing Technology of Chemotherapy Induced Peripheral Neuropathy Treatment market

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment market by Regions, Creators, Types and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Chemotherapy Induced Peripheral Neuropathy Treatment industry 2015-2019

7 Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Chemotherapy Induced Peripheral Neuropathy Treatment market by Regions

8 Gross and Gross Margin Examination

9 Marketing Traders or Distributor Examination

10 Worldwide Impacts on Chemotherapy Induced Peripheral Neuropathy Treatment Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry 2019 Market Research Report

Continued

Click here to view the full report:https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#table_of_contents

Visit link:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Research Report by Manufactures, Types, Applications and Forecast to 2025 ...

Read More...

Personalized Medicine Products Advanced by FDA in 2019 Address Root Causes of Rare Diseases, Offer Expanded Options for Cancer Patients, and Help…

February 21st, 2020 10:52 am

WASHINGTON, Feb. 21, 2020 /PRNewswire/ --In a report released this morning, the Personalized Medicine Coalition (PMC) explains how 12 personalized treatments and seven diagnostics the U.S. Food and Drug Administration (FDA) approved or cleared in 2019 will improve patient care and make the health system more efficient by addressing root causes of rare diseases, expanding treatment options for cancer patients, and targeting therapies to responder populations. The approvals and clearance decisions expand the frontiers of the rapidly evolving field of personalized medicine for the benefit of patients and health systems.

Personalized Medicine at FDA: The Scope & Significance of Progress in 2019defines personalized medicine as a field "in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms, often genetic, that cause disease or influence a patient's response to certain treatments." The report classifies 11 new therapeutic molecular entities and one gene therapy as personalized treatments. Five of those treatments are the first to address root causes of devastating rare diseases. Four others provide new options for cancer patients, and two include FDA labeling that will help patients avoid debilitating and costly adverse side effects. The report also explains how seven newly cleared or approved diagnostics will help make the health care system more efficient by targeting treatments to only those patients who will benefit from them, sparing expenses and side effects for those who will not.

"Personalized Medicine at FDA: The Scope & Significance of Progress in 2019 reminds us that personalized medicine offers new hope to patients with devastating diseases as well as opportunities to avoid prescribing therapies that will be unsafe or ineffective for certain populations of patients," said Edward Abrahams, President, PMC.

In classifying 11 of the 44 (25 percent) new therapeutic molecular entities FDA approved last year as personalized medicines, this year's report marks the sixth straight year that personalized medicines have accounted for more than 20 percent of the agency's new drug approvals. These approvals have increased sharply since 2005, when personalized medicines accounted for just 5 percent of newly approved therapies.

About the Personalized Medicine Coalition:The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit http://www.personalizedmedicinecoalition.org.

PRESS CONTACT

Christopher J. WellsVice President, Public AffairsPersonalized Medicine Coalitioncwells@personalizedmedicinecoalition.org (202) 589-1755

View original content to download multimedia:http://www.prnewswire.com/news-releases/personalized-medicine-products-advanced-by-fda-in-2019-address-root-causes-of-rare-diseases-offer-expanded-options-for-cancer-patients-and-help-target-therapies-to-responders-pmc-report-shows-301009131.html

SOURCE Personalized Medicine Coalition

Read more here:
Personalized Medicine Products Advanced by FDA in 2019 Address Root Causes of Rare Diseases, Offer Expanded Options for Cancer Patients, and Help...

Read More...

Personalized Medicine Market Worth $3.92 Trillion by 2026 – Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics – P&T…

February 21st, 2020 10:52 am

DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Personalized Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026, growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Based on the End-user, the hospital's segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals. As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

The key vendors mentioned are Abbott Laboratories, Affymetrix Incorporated, Agendia N.V, Agilent Technologies, Inc, Amgen, Inc, Asuragen Incorporated, Bayer Healthcare Pharmaceuticals, Llc, Celera Diagnostics LLC, Celgene Corporation, Roche Diagnostics Corporation, Precision Biologics Incorporated, Siemens Healthcare Diagnostics, Inc, Sigma-Aldrich Corporation, Johnson & Johnson, Novartis AG, Decode Genetics Inc., Exact Science Corporation, Exagen Diagnostics Inc., GE Healthcare, and Genelex Corporation.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Personalized Medicine Market, By Product5.1 Introduction5.2 Diagnostics5.3 Personalized Medical Care5.4 Personalized Nutrition & Wellness5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology6.1 Introduction6.2 Metabolomics6.3 Pharmacodynamics6.4 Pharmacogenetics6.5 Pharmacogenomics6.6 Pharmacokinetics6.7 Pharmacoproteomics6.8 Point-of-Care Testing6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area7.1 Introduction7.2 Autoimmune Diseases7.3 Blood Transfusion Safety7.4 Cancer Management7.5 Cardiovascular Diseases (CVD)7.6 Central Nervous System (CNS) Disorders7.7 Coagulation Therapy7.8 Diabetes7.9 Infectious Diseases7.10 Antiviral7.11 Neurology7.12 Psychiatry7.13 Oncology7.14 Immunology7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel8.1 Introduction8.2 Dietary Care Centers8.3 Hospital's Pharmacies8.4 Retail Pharmacies8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application9.1 Introduction9.2 Biomarker Identification9.3 Clinical Research Applications9.4 Companion Diagnostics9.5 Health Informatics

10 Global Personalized Medicine Market, By End-user10.1 Introduction10.2 Academic Institutes10.3 Bio and Health Informatics Companies10.4 Clinical Care and Research Laboratories10.5 Contract Research Organizations10.6 Hospitals10.7 Molecular Diagnostic Laboratories and Testing Facilities10.8 Research Laboratories10.9 Service Providers10.10 Partner10.11 Venture Capitalists10.12 Other End-users

11 Global Personalized Medicine Market, By Geography11.1 North America11.2 Europe11.3 Asia-Pacific11.4 South America11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape13.1 Abbott Laboratories13.2 Affymetrix Incorporated13.3 Agendia N.V13.4 Agilent Technologies Inc.13.5 Amgen Inc.13.6 Asuragen Incorporated13.7 Bayer Healthcare Pharmaceuticals, LLC13.8 Celera Diagnostics LLC13.9 Celgene Corporation13.10 Roche Diagnostics Corporation13.11 Precision Biologics Incorporated13.12 Siemens Healthcare Diagnostics Inc.13.13 Sigma-Aldrich Corporation13.14 Johnson & Johnson13.15 Novartis AG13.16 Decode Genetics Inc.13.17 Exact Science Corporation13.18 Exagen Diagnostics Inc.13.19 GE Healthcare13.20 Genelex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/37rw80

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-worth-3-92-trillion-by-2026---insights-into-diagnostics-medical-care-nutrition--wellness-and-therapeutics-301008591.html

SOURCE Research and Markets

More here:
Personalized Medicine Market Worth $3.92 Trillion by 2026 - Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics - P&T...

Read More...

US Researchers Provide Holistic Perspective on Extrusion-Based 3D Printing of Personalized Medicine – 3DPrint.com

February 21st, 2020 10:52 am

US researchers continue ongoing research into 3D printed pharmaceuticals, presenting their unique findings in Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials-Process Perspective.

While many have predicted that the pharmaceutical industry was perched on the edge of a massive transformation due to the advantages offered by 3D printing, there are still many ongoing studies regarding suitable printers, materials, and critical issues such as the impacts of DIY drugs and more formalized manufacturing. In this study, the researchers examine both extrusion-based FDM 3D printing and pressure-assisted micro-syringe 3D printing as they compare them to more traditional processes, along with techniques, challenges, and consider the general direction of the industry overall.

Within the pharmaceutical industry today, 3D printing has made impacts in digital fabrication of drugs, implants, drug delivery systems, and more; however, the researchers point out the importance of such processes especially in creating personalized medications. Citing the success, and FDA approval, of epilepsy drug SPRITAM, the authors stress advantages in the trend toward patient-specific treatmentand specifically, medicine.

Current pharmaceutical manufacturing practices are not costeffective for personalized medicine, state the researchers. 3D printing pharmaceuticals are more suitable than current manufacturing practices for tailored solid dosages.

Although the first waves of pharmaceutical 3D printing began with inkjet printing, strides since then have been not only impressive, but fascinating to much of the public, including:

FDM and PAM printing processes have been most attractive to users due to accessibility and affordability, the potential for fabricating and tuning complex geometries, and more.

(a) The proportion of research articles published on different types of 3D printing processes in the last five years (20152019, total 202 articles); (b) The number of published scientific articles (research and review) in the period from 2015 to 2019 which reported the use of extrusionbased (fused deposition modeling (FDM) or pressureassisted microsyringe (PAM)) 3D printing (source: Scopus database and PubMed).

Choosing the right materials is critical to the success of 3D printing medications also, along with the capability for attaining FDA approval. As a highly suitable material, polymers may be used to print the following in relation to tablets and caplets:

Polymers multifaceted utilization in solid dosage drug delivery systems solidifies its importance in pharmaceutical 3D printing applications, state the researchers.

2dimensional (2D) schematic of the extrusionbased 3D printing process: (a) fuseddeposition modeling (FDM), (b) pressureassisted microsyringe (PAM).

And while they have reviewed studies from multiple other scientists, the authors here point out that while such guides are needed, no detailed discussion on how polymers should be selectedalong with other detailsexists.

Comparison of FDM and PAM 3D printing technologies

Processing is very similar via FDM or PAM, with the extra benefit of being more environmentally friendly, offering the ability for remote control of printing, and small batch, on-demand printing.

Comparison of different processing steps required for traditional direct compression (DC) tablet manufacturing vs. advanced manufacturing, 3D printing (FDM or PAM).

Typical polymers that can be used for 3D printing in pharmaceuticals include:

Summary of polymers based on (a) water solubility and drug release type, (b) their selection for either FDM or PAM 3D printing method.

Obviously, the pharmaceutical industry is highly regulated, with good reason, and the production of medications can be complex due to stringent requirements in production for the safety of the patient. In terms of 3D printing, however, a list of challenges still present themselves such as lack of predictability and consistency in quality of product due to issues like shrinkage or warping, problems with mechanical stability and other properties, and more.

Though a large-scale production of pharmaceuticals using 3D printing might be a long way from now, personalized medicine is possible inhouse for immediate use, conclude the researchers. Future work to enable drug product manufacture using FDM and PAM 3D printing technologies should include the suitability and characterization of polymers and other excipients amenable to processing.

Polymer materials and their properties, specifically their rheology should be investigated to allow a wider formulation and 3D printing design space. A better understanding of the rheological properties of APIpolymer mixtures and their measurement is necessary for the successful 3D printing of pharmaceuticals.

What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

Characterizations required for 3D printed structure, drug, and polymer (or other functional excipients, if necessary).

Here is the original post:
US Researchers Provide Holistic Perspective on Extrusion-Based 3D Printing of Personalized Medicine - 3DPrint.com

Read More...

Jupiter Medical Center and Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, Enter Affiliation to Advance Cancer…

February 21st, 2020 10:52 am

JUPITER, Fla., Feb. 20, 2020 /PRNewswire/ -- Jupiter Medical Center is pleased to announce an affiliation with Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine, providing access to groundbreaking cancer treatments to residents in Palm Beach County and the Treasure Coast. Part of the University of Miami Health System, Sylvester is South Florida's only National Cancer Institute (NCI)-designated cancer center.

The affiliation between Sylvester Comprehensive Cancer Center and Jupiter Medical Center will enable Jupiter cancer patients to have seamless access to Sylvester's highly specialized treatments, innovative therapies, world-renowned experts and clinical trials.

Patients with highly complex or rare cancers will benefit from the specialized expertise, leading-edge technology and clinical research available at NCI-designated cancer centers, such as Sylvester. Those treatments include bone marrow transplants, CAR T-cell immunotherapy, precision medicine approaches, cancer prevention, proton therapy coming later this year, and other new methods to preventing and treating cancer.

"Our affiliation allows patients to continue to receive world-class, personalized and comprehensive cancer care at Jupiter Medical Center, while making it easier for our patients to access the experts, specialized technology and scientific breakthroughs being made at Sylvester," said Dr. Amit Rastogi, president and chief executive officer of Jupiter Medical Center. "The relative proximity of Jupiter Medical Center and Sylvester will help support collaboration and cooperation between the medical teams at both institutions."

"We have a highly-qualified team of more than 300 cancer-focused physicians and researchers working together to deliver world class expertise in cancer prevention, innovative treatments and survivorship to patients," said Dr. Stephen D. Nimer, director of the Sylvester Comprehensive Cancer Center. "This affiliation allows Sylvester to work with a hospital that shares our mission to make advanced cancer care available to a broader community. We are very happy to have an opportunity to work with Jupiter Medical Center to provide pioneering treatments to more patients from Palm Beach County and the Treasure Coast."

Dedicated nurse navigators will facilitate communication and coordination of care between the medical teams at Sylvester Comprehensive Cancer Center and Jupiter Medical Center. The agreement also provides opportunities for cancer experts from both medical centers to collaborate on patient evaluation, diagnosis, and treatment, sharing best practices to determine the best treatment plans for all types of cancer.

Jupiter Medical Center is home to the new Anderson Family Cancer Institute, a 55,000-square-foot, state-of-the-art cancer center opening in March 2020. Accredited by the American College of Radiology, the Commission on Cancer and the National Accreditation Program for Breast Centers, Jupiter Medical Center offers full spectrum of cancer care, including advanced diagnostics, personalized treatments provided by a multidisciplinary team of clinicians, support services for family and caregivers and survivorship programs.

Sylvester Comprehensive Cancer Center is one of only 71 NCI-designed centers nationwide. This designation recognizes cancer centers that meet rigorous standards for multi-disciplinary care and state-of-the-art research focused on developing new approaches to treating and curing cancer.

About Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center, part of UHealth - University of Miami Health System and the University of Miami Miller School of Medicine, is the only cancer center in South Florida designated by the National Cancer Institute. NCI designation recognizes that Sylvester has met the most rigorous standards for cancer research, beginning in our laboratories, extending to patient care, and meeting specific needs in our community. Sylvester is known as South Florida's leader in patient-focused cancer research and care, offering the only Phase 1 Clinical Trials program the first step in evaluating how patients respond to the latest investigational treatments. NCI designation further expands Sylvester's ability to provide access to novel therapies through more clinical trials and collaboration with other designated centers. Equipped with a highly qualified team of more than 300 cancer-focused physicians and researchers working together, Sylvester discovers, develops, and delivers more precision cancer care. To serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities throughout South Florida.

About Jupiter Medical Center

Ranked #1 for quality, patient safety and patient satisfaction, Jupiter Medical Center is the leading destination for world-class health care in Palm Beach County and the greater Treasure Coast. In 2019, the Leapfrog Group named Jupiter Medical Center a "Top Hospital," a distinction earned by only 6 percent of hospitals nationwide. Jupiter Medical Center is also the only hospital in Palm Beach, Martin, St. Lucie and Indian River counties to receive a 4-star quality and safety rating from the Centers for Medicare & Medicaid Services (CMS). Outstanding physicians, state-of-the-art facilities, innovative techniques and a commitment to serving the community enable Jupiter Medical Center to meet a broad range of patient needs. The region's only independent, not-for-profit hospital, Jupiter Medical Center offers specialty concentrations in orthopedics and spine care; cancer care and oncology; cardiac and vascular care; neuroscience and stroke care; women's and children's services; urgent care; and other key areas. For more information on Jupiter Medical Center, please call (561) 263-2200 or visit jupitermed.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/jupiter-medical-center-and-sylvester-comprehensive-cancer-center-part-of-the-university-of-miami-health-system-enter-affiliation-to-advance-cancer-treatment-in-palm-beach-county-301008737.html

SOURCE Jupiter Medical Center

Read the rest here:
Jupiter Medical Center and Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, Enter Affiliation to Advance Cancer...

Read More...

Single-cell Analysis Market Worth $5.6 Billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

February 21st, 2020 10:52 am

CHICAGO, Feb. 21, 2020 /PRNewswire/ -- According to the new market research report "Single-cell Analysis Marketby Cell Type (Human, Animal, Microbial), Product (Consumables, Instruments), Technique (Flow Cytometry, NGS, PCR, Mass Spectrometry, Microscopy), Application (Research, Medical Application), End User - Global Forecasts to 2025", published by MarketsandMarkets, the Single-cell Analysis Marketis projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

The growth in this market is driven by technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and the increasing incidence and prevalence of chronic and infectious diseases. However, the high cost of single-cell analysis products is expected to restrain the growth of this market to a certain extent during the forecast period.

The research applications segment accounted for the largest share of the market, by application, in 2018

Based on application, the Single-cell Analysis Market is segmented into research (cancer, immunology, neurology, stem cell, and other research applications) and medical applications (noninvasive prenatal diagnosis, in vitro fertilization, and circulating tumor cell detection). The research applications segment accounted for the largest share of the market in 2018. Increasing government initiatives in stem cell research and the wide usage of single-cell analysis in cancer research are the major factors driving the growth of the research applications segment.

Browsein-depth TOC on"Single-cell Analysis Market"

225 Tables 50 Figures252 Pages

The flow cytometry segment accounted for the largest market share in 2018

Based on technique, the market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques. The flow cytometry segment accounted for the largest market share in 2018. The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles. However, the NGS segment is projected to register the highest growth rate during the forecast period. The high growth of the NGS segment is driven by the increasing application of single-cell analysis products in drug discovery for cancer and other chronic diseases.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=171955254

North America dominates the Single-cell Analysis Market

The global market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest share of the market. The growth in this market can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

Prominent players in the Single-cell Analysis Market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=171955254

Browse Related Reports:

Cell Counting Marketby Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023

Cell Isolation/Cell Separation Marketby Product (Reagents, Beads, Centrifuge), Cell Type (Human, Animal), Cell Source (Bone Marrow, Adipose), Technique (Filtration), Application (Cancer), End User (Hospitals, Biotechnology) - Global Forecast to 2024

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Sanjay GuptaMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.com Research Insight: https://www.marketsandmarkets.com/ResearchInsight/single-cell-analysis-market.asp Visit Our Website:https://www.marketsandmarkets.com Content Source:https://www.marketsandmarkets.com/PressReleases/single-cell-analysis.asp

SOURCE MarketsandMarkets

Read the rest here:
Single-cell Analysis Market Worth $5.6 Billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Read More...

High-throughput Technologies in Drug Discovery – Technology Networks

February 21st, 2020 10:52 am

Bringing new medicines to patients struggling with serious illness is the driving force behind drug discovery and development. Originating as small molecules, drugs have shifted to large molecule therapies and will continue to shift as precision medicine is adopted. In spite of these different types of drugs, the development time to create them has not changed dramatically. It still takes 10 to 15 years to bring a drug to market. For this reason, there is tremendous interest when it comes to finding ways to develop drugs with higher throughput methods. This article highlights advances in three technology areas that show great promise to speed the drug discovery and development process.Automation and roboticsThe need for automation and robotics is not a new topic in drug discovery but an area where great progress has been and continues to be made. Automation is essential to implementing high-throughput strategies. What started out as a solution to achieve higher throughput has extra benefits. An automated process provides better data quality due to process consistency. Human error is minimized, and the presence of an audit trail allows traceability if questions arise. Automation also provides walk away freedom for the scientist to pursue other tasks.

To witness an automated set up, one may find that each automation step may not be fast in and of itself. But consider the shift away from an 8-hour employee workday to one of continuous 24-hour operation. Screening projects are now reduced by at least a factor of 3, thus yielding higher throughput.

Automation can be categorized into three general modes defined as (1) batch, (2) semi-automated, and (3) integrated. The three modes range from limited to extensive on key automation criteria which include things like flexibility, walk away capabilities, number and complexity of tasks. Batch mode, for example still requires a scientist to load stacks of plates that then are subjected to a limited step in the process. Integrated automation, the most sophisticated, is capable of carrying out multiple scheduled steps facilitated by a robotic mover. This allows unmanned operation for extended periods providing walk away or overnight convenience.1An important consideration in any automated solution is the skill requirement of the operator. More sophisticated systems will require automation programming skills often leveraging automation engineers. Specialized training from the equipment vendor may also be required. Batch automation can often be accomplished with little specialized training. Compared to ten years ago, automation today has evolved and become more democratized. This continued trend will reduce the need for specialized training in the future with more turn-key and intuitive solutions becoming commercially available.

David Ebner, Principal investigator at the Target Discovery Institute in Oxford, UK explains: There are two key limiting factors for any group trying to do high-throughput screening today. The first is the expertise to translate a benchtop assay to a high-throughput platform and the second factor is the expense. Centralized core facilities are one way to address the expense factor. And as automation becomes more turn-key, the need for specialized engineers is reduced, allowing future resources to be more research scientist driven.

The discovery and development of small molecules and antibodies targeting T cell function, as well as T cell-based cell therapies and cell manufacturing, require assays to rapidly and reliably profile T cell activation and cell health. In this app note, discover how phenotypic screening addresses these needs, using a single assay to provide rapid, optimized monitoring of cell proliferation, activation markers and cytokines.

Microfluidic technology, a more extreme form of miniaturization, addresses some of these known fluid handling challenges.4 Microfluidic chips provide the benefits of reduced volumes while replacing liquid handling mechanics with channels connected to liquid reservoirs. In some cases, the device has integrated tools such as electrodes built-in and can combine multiple operational steps. 5Microfluidic devices are also able to isolate single cells, which can be further cultured on the chip. This ability removes cellular heterogeneity on cancer cell populations as an example. Traditional drug screening methods see response information from an average of all cells. The microfluidic solution allows analysis of a single cell's antidrug response.4 In addition to this cell-on-chip model, recent advances have led to tissue-on-chip and organ-on-chip models which are still early in development. These kind of chip models may someday provide a powerful alternative to animal models.6 Because they are early in development, they are not high- throughput solutions today. But they show great promise to speed determination of drug activity, optimal combinatorial drug screening and toxicity testing in the future.4Artificial intelligenceApplied to drug discovery, artificial intelligence (AI) has been used in medicinal chemistry for designing compounds since the 1960s. 7 Machine-learning tools like quantitative structure-activity relationship (QSAR) modeling have identified potential target molecules from millions of candidate compounds. 8 Today, AI has expanded its application in drug discovery to a range of tasks from robotics control to image analysis and logistics. AI has also been applied throughout the drug discovery process from target selection, hit identification, lead optimization through to preclinical studies and clinical trials. 7, 8Dr Mohammad HamediRad and colleagues at the University of Illinois explain that with new uses of AI, "the role of researcher changes from drivers of the experiments to supervisors of the system." AI, integrated with robotic systems enables automation of the design, build, test, and learn (DBTL) cycle. This results in a platform that designs experiments, executes them, analyzes the data then optimizes and executes subsequent experiments iteratively. This closed loop discovery reduces the total number of experiments and generates the best possible optimization. The concept was demonstrated by HamediRad and colleagues in 2019. Their fully-automated platform evaluated less than 1% of possible variants and outperformed traditional screening methods by 77%.9AI platforms can cut down the development time from lead molecule to a candidate by more than half. AI predicted molecules are more likely to be correct and allow a focused effort. Time isnt wasted testing irrelevant molecules which would have been worked on otherwise and make up 90% of the molecules tested by traditional methods.10 Currently, AI can help find novel compounds which are more potent and selective using high quality screening data sets much faster and at less expense than screening alone, explains Ebner.

Personalized or precision medicine is another area where AI plays an important role. Precision medicines are a growing proportion of drugs in the industry pipeline. 11 Extensive collections of human samples (diseased and healthy) are required for biomarker identification in developing a personalized medicine. 12 Typically, all samples are sequenced using next-generation sequencing which generates massive amounts of data. AI methods of deep-learning make analysis of these big data sets possible. 8Automation Journey Guide: How To Automate Simple to Complex Workflows For Achieving Results Beyond High-throughput

Laboratory automation is playing a key role in advancing scientific research, from pharmaceutical development to diagnostics. Whether it is to automate a simple or sophisticated workflow, automation is now used in labs throughout the world to increase their capacity and throughput. In this eBook, discover a detailed guide to introducing automation to your lab.

Read this article:
High-throughput Technologies in Drug Discovery - Technology Networks

Read More...

Detailed Map of Breast Cancer Reveals the Effects of Mutations on the Tumor Landscape – Clinical OMICs News

February 21st, 2020 10:52 am

An international team of scientists, spearheaded by a 20 million ($25.9 million) award from Cancer Research UK, has developed the most detailed maps of breast cancer available, which map breast tumor samples to a resolution smaller than a single cell.

The maps, published in Nature Cancer this week, detail the intricacies and complexity of the cancer landscapecomprising cancer cells, immune cells, and connective tissueand how it varies both between, and within, tumors depending on their unique genetic makeup.

At the moment, doctors only look for a few key markers to understand what type of breast cancer someone has, said Dr. Raza Ali, junior group leader at the Cancer Research UK Cambridge Institute, and the studys lead author. But as we enter an era of personalized medicine, the more information we have about a patients tumor, the more targeted and effective we can make their treatment.

In the future, the hope is that such a map could provide clinicians with a wealth of information specific to each patients tumor at the time of diagnosis, thus providing an opportunity to match patients with the most appropriate therapy. The information would also be used to analyze tumor during a patients treatment to more clearly see how a patient is responding to their therapy and to adjust the treatment regimen based this.

In the study, the international research teams from Cancer Research UK Cambridge Institute, University of Cambridge; the University of Zrich, Switzerland; and the British Columbia Cancer Research Centre, Canada, studied 483 different tumor samples collected during the Cancer Research UK funded METABRIC study, a project that has already significantly improved the understanding of the disease by revealing that there are at least 11 different subtypes of breast cancer.

The team looked within the samples for the presence of 37 key proteins, indicative of the characteristics and behavior of cancer cells. Using a technique called imaging mass cytometry, they produced detailed images, which revealed precisely how each of the 37 proteins were distributed across the tumour.

The researchers then combined this information with genetic data from each patients sample to further enhance the image resolution. This is the first time imaging mass cytometry has been paired with genomic data.

These tumor blueprints expose the distribution of different types of cells, their individual characteristics and the interactions between them.By matching these pictures of tumors to clinical information from each patient, the team also found the technique could be used to predict how someones cancer might progress and respond to different treatments.

Professor Carlos Caldas, from the Cancer Research UK Cambridge Institute and co-author of the study said: Weve shown that the effects of mutations in cancer are far more wide-ranging than first thought.They affect how cancer cells interact with their neighbours and other types of cell, influencing the entire structure of the tumour.

The research was funded by Cancer Research UKs Grand Challenge initiative. By providing international, multidisciplinary teams with 20 million grants, this initiative aims to solve the biggest challenges in cancer.

This team is making incredible advances, helping us to peer into a future when breast cancer treatments are truly personalized, said Dr. David Scott, director of Grand Challenge at Cancer Research UK. Theres still a long way to go before this technology reaches patients, but with further research and clinical trials, we hope to unlock its powerful potential.

Originally posted here:
Detailed Map of Breast Cancer Reveals the Effects of Mutations on the Tumor Landscape - Clinical OMICs News

Read More...

PRECISION MEDICINE MARKET 2020: INDUSTRY ANALYSIS AND DETAILED PROFILES OF TOP INDUSTRY PLAYERS ARE NEON THERAPEUTICS, MODERNA, INC, MERCK & CO.,…

February 21st, 2020 10:52 am

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of[emailprotected]http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See original here:
PRECISION MEDICINE MARKET 2020: INDUSTRY ANALYSIS AND DETAILED PROFILES OF TOP INDUSTRY PLAYERS ARE NEON THERAPEUTICS, MODERNA, INC, MERCK & CO.,...

Read More...

Why Companies Need GxP for their Digital Transformation Projects Now, Upcoming Webinar Hosted by Xtalks – PR Web

February 21st, 2020 10:52 am

Xtalks Life Science Webinars

TORONTO (PRWEB) February 21, 2020

Pharmaceutical manufacturers are under increasing pressure to fast-track technological innovation to improve their manufacturing operations in order to adapt to new approaches like Industry 4.0 and continuous manufacturing, combat the growing and intense competition and keep up with the increasing demand for personalized medicine and therapies. But with an industry with the worlds tightest regulations and complex value chains, what are the correct steps to reaching operational intelligence in a GxP compliant manner with end-to-end data integrity?

Attend this webinar to learn:

Join speakers from Bigfinite including CEO Pep Gubau and Product Owner Christina Fernandez in a live webinar on Monday, March 9, 2020 at 1pm EDT to learn about how you can gain better knowledge of your operational realities and why you should consider GxP compliance today rather than delaying work to establish these regulatory systems now.

For more information or to register for this event, visit Why Companies Need GxP for their Digital Transformation Projects Now.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Read the rest here:
Why Companies Need GxP for their Digital Transformation Projects Now, Upcoming Webinar Hosted by Xtalks - PR Web

Read More...

Why keeping an eye on the effects of CVS can promote wellness in the workplace – Bdaily

February 21st, 2020 10:51 am

With more and more digital technology (and screen-based work) being introduced across all areas of business, and increased use of smartphones and digital devices overall, Computer Vision Syndrome (CVS), or screen fatigue, is on the rise.

Computer Vision Syndrome (CVS) is caused by looking at a computer or other display device for prolonged, uninterrupted periods of time. Because screen pixels constantly refresh eyes are always having to refocus which results in eye muscles becoming fatigued.

It is also proven that people blink less frequently when staring at a screen for long periods, which causes eyes to dry out and in some cases can result in blurred vision. Glasses wearers that have incorrect or an out of date lens prescription can also be more susceptible to CVS.

Symptoms of CVS include eyestrain, headaches, blurred vision, dry eyes and neck and shoulder pain.

These effects can impact on productivity in the workplace and encouraging positive habits among employees is now an essential part of any wellbeing in the workplace schemes.

As a world-leading innovator in spectacle lens technology, Essilor is advising screen users to:

follow the 20:20:20 rule. Every 20 minutes, look at something 20 feet away for 20 seconds.Or take part in eye yoga. Look to the left, hold the position, repeat looking right. Look up, hold the position, repeat looking down. Repeat four times, closing your eyes and relaxing in between.

take regular breaks from screens and to go outside. Looking at objects in different distances and in natural light can be beneficial for your eyes and sight.

have regular eye tests. Eyes should be examined every two years as routine; many eye problems will be detected this way the earlier problems are identified, the easier they will be to rectify.

use specialist computer lenses, like Eyezen lenses with DualOptim technology, designed to prevent or reduce eye strain or visual fatigue. Different waves lengths of light, such as Ultraviolet and Blue-Violet light, can also cause premature eye ageing. Eye Protect systems embedded into lenses can also filter out Blue-Violet light.

Dr. Andy Hepworth from Essilor comments: While computer vision syndrome and digital eyestrain is on the rise, its not a permanent vision problem, but something that can be controlled with some simple changes in behaviours.

We know high levels of digital usage is not going away in fact a recent screen time survey showed most Brits do not intend to reduce the amount of time spent staring at screens; therefore it makes sense to be aware of the need to utilise new products better suited as lifestyles change.

While our scheme encourages people to look up and give their eyes a rest, which in turn will also help with their concentration and day to day mental health, were also offering a solution with innovative lenses. Our latest innovative solutions can rectify specific problems caused by heavy usage of digital technology.

We recognise every person is an individual and the lifestyle choices they make day to day will affect their eyesight. By encouraging people to following the 20:20:20 rule and refreshing eyes during the day, we hope to promote better eye health within UK businesses.

Follow this link:
Why keeping an eye on the effects of CVS can promote wellness in the workplace - Bdaily

Read More...

Dad in race against time to see his baby born before he goes completely blind – Mirror Online

February 21st, 2020 10:51 am

A young dad is in a race against time to see his daughter born before he loses his eyesight forever.

Charlie Macaulay, 21, from east Hull, has said he just wants to see his daughter and watch his partner walk down the aisle before he loses his eyesight completely due to his diabetic condition.

The dad-of-one has been diabetic for 18 years, following his diagnosis one week after his third birthday.

Complications with his condition led to the development ofdiabetic retinopathy in December, which has caused a rapid deterioration in his eyesight.

Now blind in his right eye and with poor vision in his left, Charlie said he just wants to see the arrival of his daughter in July and his pregnant bride-to-be Billie Smith in her wedding dress in May before he becomes permanently blind.

"I'd marry her tomorrow if I could," Charlie told Hull Live.

"I just want to see her in her dress and I want to see my wedding and my little girl before my eyes go."

Charlie's health complications did not take effect until he joined secondary school, when he started getting bullied for having an insulin pump attached to his stomach to regulate his blood sugar levels.

"That's when I used to mistreat it and try to pretend it wasn't there," he said. "That was a tough time."

After experiencing problems with his vision at the end of last year, Charlie went to the hospitalin December and was told about the imminent deterioration of his eyesight.

Six operations in the space of just a few weeks later and Charlie has only partial vision in just one of his eyes.

"Now I'm struggling to see and it's really tough," he said.

"I can't see my phone screen or cars when I'm crossing the road. I've fallen over a few times because I can't see kerbs.

"I can't really go out on my own now, I've got to have someone with me."

But Charlie has been supported by Hull charity Sight Support and is in the process of enrolling for white cane training.

A liaison support worker has also put him in touch with a local blind football team.

"I just don't want to lose my independence, it's had a massive effect over the past couple of months," he said.

"I struggle with my mental healthanyway and it's hard to take in. Sometimes I wonder how I keep it together without having some sort of breakdown."

Now Charlie said he is hoping to raise awareness not just of diabetes in younger people and the potential complications it can cause, but the potential effects onmental healthtoo.

"I struggle to speak to people at the best of times but I want to start taking to spread awareness," he said.

"A lot of people think, 'Oh you can't have sugar,' but it isn't that.

"I've had a few people when I tell them I'mdiabeticsay, 'But you're not overweight.'

"I don't think we get taught enough about it, especially younger people.

"It can affect everybody, every age group, but in younger people it needs to be put out there how serious it can be and the effects it can have.

"And I have to wear sunglasses now too because I'm really sensitive to light, but people just see a young lad wearing sunglasses in the middle of February and think, who does he think he is?

"I want to spread awareness of the mental health side of it as well to let people know the seriousness of it, but also that it's alright to talk."

He said the biggest source of comfort has been his family, including his long-term partner Billie and their two-year-old son Freddie-James.

And he said planning his wedding is helping to keep his mind off his condition.

"My family are brilliant, they're always there for me if I need to talk," Charlie said.

"Billie's struggling but she doesn't show it, she hasn't left my side the whole way through. She's there 100 per cent."

Charlie's mum Sarah, 41, is even running the London Marathon in April to help raise awareness and money for Diabetes UK.

She has set up JustGiving pageto help support her cause.

"I'm really proud, I can't believe she's actually doing it," Charlie said.

"It's one of the biggest charity events in the country, if not the world, so I'm massively proud of her and just want to help her in any way possible."

Mum Sarah said: "It was awful at first coming to terms with it, but then he did great.

"But once he got to secondary school he just wanted to pretend he didn't have it and that's had a knock-on effect. He just wanted to be the same as everybody else.

"People don't know how serious can be or how important to get the right support. It's very serious and the complications that come with it are huge.

"But now he's got all his family pulling together around him.

"They've got the wedding booked for May 9 and we're all rallying round for him, but they want to bring it forward.

"That's his dream - to see Billie in her wedding dress and their baby who's on the way in July.

"They've been together for such a long time and she's been amazing. He wouldn't have been able to do this without her or their little boy.

"A lot of people don't know about it, they know he's struggling but they didn't know how serious the condition has got with his eyesight.

"So coming out like this is a big step for him."

Anybody who wants to support Sarah and Charlie's cause can donate to the JustGiving page here.

More here:
Dad in race against time to see his baby born before he goes completely blind - Mirror Online

Read More...

Retinal Prosthesis Market Trade Outlook And Information Collected 2020-2026 – Instant Tech News

February 21st, 2020 10:51 am

The report titled on Retinal Prosthesis Market report offers in-intensity analysis of the worldwide market size (Production, Value and Consumption), splits the breakdown (data status 2014-2019 and 6 Forces forecast 2020 to 2026), by manufacturers, region, type and application. Retinal Prosthesis market competitive landscape provides details by topmost manufactures like (Philips Healthcare, Retina Implant, Second Sight Medical Products, Bionic Eye Technologies, Bionic Vision Australia, VisionCare Ophthalmic Technologies, Abbott Vascular), including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Retinal Prosthesis Sales and Revenue Generated, Market Share, Price, Production Sites And Facilities, SWOT Analysis, Product Launch. In the end, there are 4 key segments covered in this Retinal Prosthesis market report: Competitor Segment, Product Type Segment, End Use/Application Segment and Retinal Prosthesis industry geography segment.

Get Free Sample PDF (including full TOC, Tables and Figures)of Retinal Prosthesis[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2161980

Retinal Prosthesis Market Report Offers Comprehensive Assessment of:

1) Executive Summary, 2) Retinal Prosthesis Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Retinal Prosthesis Market Background, 7) Retinal Prosthesis industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Retinal Prosthesis Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Retinal Prosthesis Market:Retinal Prosthesis is being used for improving eyesight of people with partial or complete blindness. The technology is still in its nascent stage hence a mixed speculation continues to hover around it.

Visual devices such as bionic eye and visual prosthesis are expected to have bigger impact in years to come, which in turn will pave the way for retinal implant market.

The global Retinal Prosthesis market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Retinal Prosthesis market based on company, product type, end user and key regions.

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Argus II Implantable Miniature Telescope

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

People with Partial Blindness People with Complete Blindness Retina Implant Alpha AMS

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2161980

The report offers in-depth assessment of the growth and other aspects of the Retinal Prosthesis Market in Important Countries (Regions), including:

Important Key Questions Answered In Retinal Prosthesis Market Report:

What will the Market Growth Rate, Overview, and Analysis by Type of Retinal Prosthesis in 2026?

What are the key factors affecting market dynamics? What are the Drivers, Challenges, and Business Risks in Retinal Prosthesis market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Retinal Prosthesis market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Retinal Prosthesis Market Share

What are the Opportunities and Threats Faced by Manufacturers in the global Retinal Prosthesis market?

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]z.us

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the rest here:
Retinal Prosthesis Market Trade Outlook And Information Collected 2020-2026 - Instant Tech News

Read More...

All you need to know about cosmetic surgery in UAE – Gulf News

February 21st, 2020 10:50 am

Image Credit: Getty Images/iStockphoto

Dubai: Myra, J, a belly dancer working at a Dubai hotel, was unhappy that saddle bags on her thighs were making her performance less graceful and she feared she would be replaced in her job. So on a weekend, she checked into a leading aesthetic clinic and the surgeon trimmed the pockets of fat around her thighs, sculpting her body back into perfect shape. It took her a week to recover and get back to work, but she is delighted with her shapely thighs and feels happier than ever before.

Nina M., (52), always loved how beautiful her eyes were and how youthful her cheeks looked. However last year, as she got busy with her sons marriage preparations, she started to experience bouts of anxiety at the sight of slowly encroaching bags under her eyes and a slight droop in her cheeks. I wanted to look and feel my best and thought a filler and a round of botox were harmless indulgences. It took me just an hour at the clinic and the results were amazing. I am glad I was able to stop the onslaught of aging in time. Its beautiful to age gracefully, but we all do use creams and gels to delay the process. I think of these minor injectibles as tools in our make-up bag. I have used fillers and Botox twice since last year, combined with my beauty regimen. I feel it has given me not just confidence but also psychological boost. I would recommend it to everyone.

Anna M was a physical trainer but vexed with her body shape as she had a masculine build. This was affecting her work as most women were intimidated by her personality and she was losing self-confidence. Four years ago, she went in for breast implants and her life changed. People talk about getting addicted to cosmetic surgery. But that is not so. Most people approach a cosmetic surgeon only when they cannot deal with a physical issue themselves and just like one needs medicine when one is ill, cosmetic surgery acts as a solution to boost confidence and self-esteem. Look at how people have reclaimed their health with gastric bypass!

- Dr Sanjay Parashar, chairman, Scientific of the Emirates Plastic Surgery Society

Changing the world one person at a time and providing them with an incredible burst of confidence, aesthetic and cosmetic surgeons in the UAE have built a practice of reliability that can take as little as one hour to a day to transform your personality. Welcome to the multi-million dirham cosmetic surgery industry in the UAE that is the toast of medical tourism in the region, With a high footfall of Gulf and Asian medical tourists as well as resident expatriates, the industry has accelerated at a speed that is making Dubai be hailed as the new Beverly Hills of the Middle East.

Cosmetic or Plastic Surgery?

These are two different concepts. Cosmetic surgery refers to aesthetic surgery and revolves around enhancement of physical features of an individual and is elective. This includes procedures such as rhinoplasty, face and cheek enhancement, brow lifts, neck and eyelid lift, face peels, laser resurfacing, botox fillers, peels, laser hair removal, breast augmentation, tummy tucks, liposuction, hair implants and dental veneers.

Plastic surgery, on the other hand, is a surgical speciality dealing with life-saving procedures of re-construction of the face and body owing to congenital defects, disfigurement due to accident, trauma, burns, tumour removal due to diseases such as cancer. In most cases, plastic surgery is not elective.

Dh12b Medical tourism sales in 2018

Since the time pop stars began to inundate Instagram with images of their perfect bodies, dazzling smiles, flawless skin and enviable hair volume, elective procedures have become commonplace with teenagers as young as 13 who are going in for instant fixes. While some procedures require a couple of days of hospital stay and being out of circulation for a while, many quick fixes are carried out during lunch breaks in one-hour durations.

Highest Per Capita cosmetic surgeons in UAE

Dr Sanjay Parashar, chairman, Scientific of the Emirates Plastic Surgery Society, told Gulf News: Cosmetic surgery tops the list in medical tourism in Dubai and according to a 2015 report of Dubai Health Authority (DHA), Dubai has the highest number of cosmetic surgeons per capita in the region - about 50 specialists for a million people.

- Dr Zuhair Al Fardan, President of the Emirates Plastic Surgery

Dr Parashar added: The field has grown beyond expectations and much of the credit goes to the development of a world-class infrastructure in this field and the corresponding health regulations. Today, in Dubai, most Day Care Surgery centres where most of the plastic surgery procedures are carried out have the best international accreditations.

Dr Zuhair Al Fardan, President of the Emirates Plastic Surgery, said,Much of the advancement in plastic and cosmetic surgery is work in progress as surgeons are constantly upgrading themselves with techniques, technologies. The UAE is keeping abreast of the best that is taking place in the world. In the last five years or so, there have been tremendous advancements in cosmetic and plastic surgery in the UAE. We have the top plastic surgeons of the world come here to do surgeries and the UAE hosts two major international plastic surgery conferences each year.

Soaring revenues

With greater acceptance and broadening of scope for the discipline, it is evident that plastic surgery is a major revenue earner and places UAE as one of the leading medical tourism destinations in the region. From a price range of Dh150-250 for a filler to Dh40,000 for a detailed body sculpting procedure, these procedures are money-spinners.

Together, the plastic and cosmetic surgery is a multimillion dirham business in the UAE. While there are no exact figures available, safe estimates can be made, say surgeons. Lets take the emirate of Dubai. There are 30 hospitals in Dubai, of which 70 per cent are internationally accredited. The emirate aims to build 22 hospitals by 2020 - 18 private and 4 public hospitals. At least 50 per cent of these offer cosmetic and plastic surgery options. Besides that there are about 150 Day Care Surgery centres and 400 aesthetic clinics in Dubai. All of them offer a bouquet of cosmetic surgery procedures and their average annual revenue is between Dh4-6 million a year. If one were to compute that with the numbers of facilities including hospitals, the annual revenue from cosmetic surgery would run into many millions of dirhams annually.

High on medical tourism

Currently, Dubai aims to attract 500,000 medical tourists a year by end 2020. In a short priod of time, Dubai has managed to be ranked 17 among the top 25 global destinations for medical tourism and cosmetic surgery, along with fertility, orthopaedic, dental and wellness disciplines in the list of most-billed medical procedures.

As per statistics, about 46 per cent of the current medical tourists in Dubai come from Asian countries, 25 per cent from GCC and Arab countries and 13 per cent from African countries, and the remaining 16 per cent from other countries, mainly the UK and Commonwealth of Independent States (CIS) countries. In fact, 40 per cent of tourists who come to Dubai come only for medical tourism.

- Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai

Medical tourism sales topped Dh12 billion in 2018, with a 5.5 per cent overall increase in medical tourists. Dubai attracted a total of 640,542 international and domestic medical tourists in 2018 (51 per cent were international patients). European tourists consisting mostly of UK, French and Italian citizens, share 16 per cent of health and wellness tourists. A substantial medical tourism revenue, it is evident, is earned through plastic and cosmetic surgery.

Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai, remarked: American Hospital Dubai, is one of the few facilities offering both comprehensive reconstructive and cosmetic surgery services. Our plastic surgeons are fully trained in both reconstructive and cosmetic surgery so we see a wide-ranging case mix, from severe trauma cases to cancer cases and of course, those opting for cosmetic surgery.

The most popular cosmetic surgery is body contouring namely abdominoplasty and liposuction, sometimes combined with a breast lift the mommy make-over. Typically, these patients would be female, who done with having children and raising them, now wish to address the changes in their body. I also see a large number of male patients who want to correct problems associated with their chest with the help of liposuction, said Dr Conroy.

Non-surgical treatments (neuro-modulators, fillers, etc) are still very popular and I have seen a trend in that patients are starting with such treatments at an earlier age.

Given the prestigious reputation of the hospital and the Dubai governments plan to promote medical tourism, I have noticed a huge influx of patients from Africa, Nigeria and Ghana in particular. These patients come mainly for cosmetic surgery, knowing that they are in the hands of a highly qualified surgeon, in a safe, luxurious facility, with standards second to none, said Dr Conroy.

Top six cosmetic surgery procedures in town

The procedures can be divided into categories:

Does health insurance cover plastic surgery?

Dr Parashar said: Lumps, bumps, nerve and tendon transfer, skin transplant, etc, are all covered. Few people know that plastic surgery has a regenerative and reconstructive role to play in case of congenital and disease deformities. Reconstructive surgery such as correction of birth deformities such as a tuberous breast, cleft lip, hand deformities, skin transplant following burns, road trauma and breast augmentation and reconstruction following a mastectomy and rebuilding after a tumour resection is all covered under all leading health insurances. There is also new kinds of stem cell therapy being used to regenerate tissues and nerves especially in diabetic patients.

Know the regulations:

The DHA has made it mandatory for all Day Care Surgery Centres, most of who carry out aesthetic procedures, to have one leading international accreditation from Canada, US, UK or Australia. These accreditations were earlier mandatory for hospitals only, but from 2020, all Day Care Surgery centres compulsorily must have an international accreditation. This ensures that an independent, international medical body enforces global health standards to grant them certification and in case of a sentinel event, conducts its independent inquiry and downgrades these places in case of a serious lapse. DHA on its own has issued a 25-page manual on quality and regulations that is to be followed at all centres.

A close examination of the Day Care Surgery centres indicates several layers of quality control.

Pre surgery quality: This involves free consultation, especially in case of a second opinion or a first time patient seeking to enquire about a procedure based on his/her requirement. When a patient uploads a request on the website of a centre from anywhere in the world, the centre has to provide a detailed consultation free of charge.

Services available to a patient: Once the patient is convinced and comes in person to consult the doctor, quality is upheld in the pre-diagnostic tests that the patient has to undergo.

Infrastructure quality: DHA has graded Day Care Centres into A, B and C categories based on the level of medical facilities that can be accessed by a patient. Anaesthesia methods such as oral, epidural and general also help classify centres. For instance, hair transplant procedures can only be carried out in B and above grade clinics. Day Care Centres that conduct surgeries under general anaesthesia much be equipped with the Advance Cardiac Life Support (ACLS) with their surgeons and registered nurses being certified as trained in administering ACLS to a patient.

Patient safety protocol: There are very specific guidelines for patient safety and the doctor/surgeon must explain the procedure in detail to the patient and his/her family and obtain a written consent to go ahead after ascertaining that all risks and side-effects have been clearly explained to the patient.

Post-operative regulation: There are specific protocols for discharge of patients undergoing cosmetic surgery. Although ambulatory care means the patient has to be discharged within the same day, there is a specification about asking the patient to desist from long-distance travel, specific rehabilitative work to be carried out from the next day for which the patient has to be within Dubai and also specific instructions when an overseas patient is declared fit to fly out of the country. When a patient flies out, he or she is provided with a proper review and notes, with instructions for overseas rehabilitation protocol with reference notes for the rehabilitation instructor and instructions for medication and periodic reviews.

Accountability

The law is clear, said Dr Al Fardan, The DHA regulations constitutes an accountability committee and holds an enquiry to fix the liability. If the centre is found guilty, its licence can be suspended or cancelled depending on the extent of guilt. If the surgeon, anaesthesiologists, nurse and technicians are found guilty, their license to practice is suspended or cancelled. If the crime is lighter, then both the centre and the team are let off with serious warnings. In case of disability following a surgery, the team examines the extent of disability and calculates the financial compensation to the patient. In case of fatality following a surgery, the is provision to pay blood money.

Read more from the original source:
All you need to know about cosmetic surgery in UAE - Gulf News

Read More...

Why the Coronavirus Seems to Hit Men Harder Than Women – The New York Times

February 21st, 2020 10:48 am

The coronavirus that originated in China has spread fear and anxiety around the world. But while the novel virus has largely spared one vulnerable group children it appears to pose a particular threat to middle-aged and older adults, particularly men.

This week, the Chinese Center for Disease Control and Prevention published the largest analysis of coronavirus cases to date. Although men and women have been infected in roughly equal numbers, researchers found, the death rate among men was 2.8 percent, compared with 1.7 percent among women.

Men also were disproportionately affected during the SARS and MERS outbreaks, which were caused by coronaviruses. More women than men were infected by SARS in Hong Kong in 2003, but the death rate among men was 50 percent higher, according to a study published in the Annals of Internal Medicine.

Some 32 percent of men infected with Middle East Respiratory Syndrome died, compared with 25.8 percent of women. Young adult men also died at higher rates than female peers during the influenza epidemic of 1918.

A number of factors may be working against men in the current epidemic, scientists say, including some that are biological, and some that are rooted in lifestyle.

When it comes to mounting an immune response against infections, men are the weaker sex.

This is a pattern weve seen with many viral infections of the respiratory tract men can have worse outcomes, said Sabra Klein, a scientist who studies sex differences in viral infections and vaccination responses at the Johns Hopkins Bloomberg School of Public Health.

Weve seen this with other viruses. Women fight them off better, she added.

Women also produce stronger immune responses after vaccinations, and have enhanced memory immune responses, which protect adults from pathogens they were exposed to as children.

Updated Feb. 10, 2020

Theres something about the immune system in females that is more exuberant, said Dr. Janine Clayton, director of the Office of Research on Womens Health at the National Institutes of Health.

But theres a high price, she added: Women are far more susceptible to autoimmune diseases, like rheumatoid arthritis and lupus, in which the immune system shifts into overdrive and attacks the bodys own organs and tissues.

Nearly 80 percent of those with autoimmune diseases are women, Dr. Clayton noted.

The reasons women have stronger immune responses arent entirely clear, and the research is still at an early stage, experts caution.

One hypothesis is that womens stronger immune systems confer a survival advantage to their offspring, who imbibe antibodies from mothers breast milk that help ward off disease while the infants immune systems are still developing.

A stew of biological factors may be responsible, including the female sex hormone estrogen, which appears to play a role in immunity, and the fact that women carry two X chromosomes, which contain immune-related genes. Men, of course, carry only one.

Experiments in which mice were exposed to the SARS coronavirus found that the males were more susceptible to infection than the females, a disparity that increased with age.

The male mice developed SARS at lower viral exposures, had a lower immune response and were slower to clear the virus from their bodies. They suffered more lung damage, and died at higher rates, said Dr. Stanley Perlman, a professor of microbiology at the University of Iowa who was the senior author of the study.

When researchers blocked estrogen in the infected females or removed their ovaries, they were more likely to die, but blocking testosterone in male mice made no difference, indicating that estrogen may play a protective role.

Its an exaggerated model of what happens in humans, Dr. Perlman said. The differences between men and women are subtle in mice, its not so subtle.

Health behaviors that differ by sex in some societies may also play a role in disparate responses to infections.

China has the largest population of smokers in the world 316 million people accounting for nearly one-third of the worlds smokers and 40 percent of tobacco consumption worldwide. But just over 2 percent of Chinese women smoke, compared with more than half of all men.

Chinese men also have higher rates of Type 2 diabetes and high blood pressure than women, both of which increase the risk of complications following infection with the coronavirus. Rates of chronic obstructive pulmonary disease are almost twice as high among Chinese men as among women.

In the United States, women are more proactive about seeking health care than men, and some small studies have found the generalization applies to Chinese students at universities in the United States, as well.

In unpublished studies, Chinese researchers have emphasized that patients whose diagnoses were delayed, or who had severe pneumonia when they were first diagnosed, were at greatest risk of dying.

One study of 4,021 patients with the coronavirus emphasized the importance of early detection, particularly in older men. And men have been turning up in hospitals with more advanced disease.

But in areas of China outside Hubei Province, the disease's epicenter and where the majority of those affected are concentrated, the patterns are different: The disease appears to have dramatically lower mortality rates, and men are being infected at much higher rates than women, according to the Chinese C.D.C. analysis.

[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]

Men may have a false sense of security when it comes to the coronavirus, said Akiko Iwasaki, a professor of immunology at Yale University who studies why some viruses affect women more severely.

Gathering and analyzing data about the new virus by sex is important both for the scientists studying it and for the general public, experts said.

Since the start of the outbreak, for example, public health officials have emphasized the importance of washing hands well and often, to prevent infection. But several studies have found that men even health care workers are less likely to wash their hands or to use soap than women, Dr. Klein said.

We make these broad sweeping assumptions that men and women are the same behaviorally, in terms of comorbidities, biology and our immune system, and we just are not, Dr. Klein said.

Read more:
Why the Coronavirus Seems to Hit Men Harder Than Women - The New York Times

Read More...

Recently Discovered Immune Cell Type May Be Key to Improving Pancreatic Cancer Immunotherapy – On Cancer – Memorial Sloan Kettering

February 21st, 2020 10:48 am

Summary

Current immunotherapies dont work for most people with cancer. Researchers have identified an overlooked immune cell type that may react to targeted therapies to rally a more powerful immune response in more cancer patients.

Immunotherapy is showing great promise for treating cancer. But so far, this approach has been effective in only about 20% of all cancers. To advance those results, researchers are looking for new ways to mobilize the immune system to destroy tumors.

Most immunotherapy drugs act on one type of immune cells called T cells. Drugs called checkpoint inhibitorsrelease the brakes on these cells, spurring them to mount an attack against a tumor. Researchers have learned that checkpoint inhibitors seem to work best in people whose tumors have been invaded by T cells sensing some kind of threat from the cancer before the treatment is started.

The problem is that most tumors dont have many T cells in them. In order to design an immunotherapy that works on more people, researchers have been looking for additional immune cell types to rally against cancer.

Now, an MSK research team reports finding a promising candidate: a group of immune cells called innate lymphoid cells (ILCs). These cells are present in many different tissues and appear to have mild antitumor effects in their normal resting state. The researchers showed that activating ILCs with drugs mobilizes T cells to shrink pancreatic cancer tumors. This could be an important step, as pancreatic cancers have not responded to checkpoint inhibitor drugs.

We think this is an important finding both for pancreatic cancer research and cancer immunotherapy overall, says Vinod Balachandran, a surgeon-scientist affiliated with theDavid M. Rubenstein Center for Pancreatic Cancer Researchand a member of theParker Institute for Cancer Immunotherapy. We are learning there are multiple ways to use the immune system to fight cancer. We think this is a sign that new immunotherapies are on the horizon.

Dr. Balachandran made the discovery in collaboration with cancer immunologistsTaha Merghouband Jedd Wolchokof the Human Oncology and Pathogenesis Program. The finding is reported today in Nature.

This is a novel treatment that works together with one of the most successful immunotherapies we have today.

ILCs are part of the bodys innate immune system where immune cells are programmed to put up an initial defense against infections and other threats, and further amplify the immune response by activating T cells. But ILCs were discovered only 10 years ago, so they have not been the focus of immunotherapy efforts. Now, innate immune cells are beginning to draw more interest from the cancer-research community. Dr. Balachandran and colleagues investigated if and how these cells played a role in the bodys response to cancer.

For the Nature study, the team looked in human pancreatic tumors to see if ILCs were present. They saw that a subtype of these cells called ILC2s were present in larger numbers in tumors compared with normal organs, suggesting they were responding to the tumors. The researchers also found that pancreatic cancer patients with more ILC2s in their tumors lived longer, suggesting ILC2s possibly had an anticancer function.

The team then tested if ILC2s could help control tumors in mice. Removing ILC2s caused pancreatic tumors to grow faster.

We thought, if these cells have protective tendencies against cancer, maybe we can figure out ways to activate them, Dr. Balachandran says.

ILC2s have receptors on their surface that control whether they multiply. The researchers found that dosing the ILC2s with a protein called interleukin 33 (IL-33) activated them, and caused both them and T cells to expand, which in turn caused tumors to shrink. IL-33 did not shrink tumors in mice that didnt have ILC2s, proving the ILC2s were the key cells mediating the effects.

The research team then looked for ways to further amp up ILC2 antitumor activity. Checkpoint proteins on the surface ofT cells act as brakes to prevent them from attacking the bodys own tissues. But this also limits the T cells antitumor activity. As ILC2s are related to T cells, Dr. Balachandrans team wondered whether checkpoint proteins also acted as brakes on ILC2s.

Immunotherapy at MSK

Cancer is smart, but your immune system is smarter. Discover how Memorial Sloan Kettering is deploying immunotherapy to fight cancer.

They discovered that when activated by IL-33, ILC2sexpress an important checkpoint protein on their surface called PD-1. This has interesting immunotherapy implications: PD-1 is one of the most important brakes on T cells, yet PD-1-blocking checkpoint inhibitors have not worked well against pancreatic tumors. This suggested treating mice with IL-33 may make pancreatic tumors sensitive to PD-1-blocking checkpoint inhibitors.

When the researchers gave IL-33 plus a PD-1 inhibitor to the mice, the tumors shrank even more. Activating ILC2s by adding IL-33 appeared to be the key for PD-1 checkpoint inhibitors to work well against the mouse pancreatic tumors.

Dr. Balachandran and his team are currently working on developing a drug that can activate ILC2s in humans as the next step.

This is a novel treatment that works together with one of the most successful immunotherapies we have today, Dr. Balachandran says. This could be a way to sensitize cancers that typically would not respond to PD-1 checkpoint inhibitors.

Read the original:
Recently Discovered Immune Cell Type May Be Key to Improving Pancreatic Cancer Immunotherapy - On Cancer - Memorial Sloan Kettering

Read More...

Dr. Katz: A healthy lifestyle will be best defense against coronavirus threat – Your Valley

February 21st, 2020 10:48 am

Dr. Steven Katz

(Photo by Aaron Kes Photography)

Dr. Steven Katz

Coronavirus is on the verge of being the next worldwide pandemic.

Thousands of people, mostly in China, have contracted the virus. However, at least two Arizonans are suspected of having the virus.

With no known cure for this virus, researchers are working furiously to find a way to treat those with this potentially deadly infection.

And while the world is focused on a cure, not enough of the conversation is focused on the things people can do to avoid contracting the disease.

Naturopathic doctors, however, are opting to address just that.

As with most of these epidemics, the people who generally die are the people with weak immune systems. Naturopathic physicians are combating this issue by using natural and safe approaches rather than through chemicals created in the lab that just suppress our immune systems.

Naturopathic physicians take a holistic approach to treating patients and eschew from prescribing pharmaceuticals unless deemed necessary. Just like conventional medical doctors, naturopathic physicians undergo a four year medical school doctoral program. The difference is that naturopathic physicians look to natural solutions to cure any of the bodys ailments.

And our solutions to avoiding diseases and viruses such as the coronavirus are particularly prescient today as the world confronts this pandemic. I have a practice in Scottsdale where I stress to my patients that the best way to fight off something like the coronavirus is living a healthy lifestyle where a strong body and immune system can create a barrier to many different infections.

To promote a strong immune system, we must maintain a healthy diet and lifestyle. An exercise regimen that combines cardio and strengthening as well as a healthy diet is an integral part to promoting a strong immune system.

A diet rich in fruits, vegetables, and healthy fats while avoiding processed non-nutritious foods creates an immune system ready for whatever the world throws at us and allows our bodies to be protected from these aggressive viruses.

A treatment to consider that you may not have heard of is intravenous dosages of immune system boosting vitamins. Supplements such as vitamin C, echinacea, elderberry, and garlic are all beneficial nutrients to help fight off an infection. However, many of them are limited due to dosing restrictions and absorption ability.

When you do an IV of vitamin C, zinc and selenium, these nutrients get absorbed right into the blood stream and provide maximum immune system benefits and protection both treating and preventing many infections.

So as the world grows more concerned about the coronavirus, the best defense against this new disease is to adhere to a healthy lifestyle and build up our immune systems to fight off any attempt by the virus to attack the body.

Seeing a naturopathic physician is a great way to start protecting your health!

To find a naturopathic doctor near you, please go to http://www.aznma.org.

Editors Note: Dr. Steven Katz, NMD is a Scottsdale-based naturopathic doctor, and president of AZNMA.

Go here to see the original:
Dr. Katz: A healthy lifestyle will be best defense against coronavirus threat - Your Valley

Read More...

Page 671«..1020..670671672673..680690..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick